molecules of the month


oral QD myosin inhibitor (IC50 = 1.4 µM)

Ph. II candidate for cardiomyopathy (5-30 mg)

from HTS w/ bovine cardiac muscle myofibrils

Journal of Medicinal Chemistry

Cytokinetics, South San Francisco, CA

Chemical structure of molecule Aficamten
1 min read

The Cytokinetics next-generation myosin inhibitor, aficamten, is a phase II candidate for genetic hypertrophic cardiomyopathies, and is orally dosed between 5-30 mg QD. It follows BMS’s mavacamten (acquired from Myokardia in a $13.1B deal), whose NDA is under review by the FDA. This class of molecules is intended to address hypertrophic cardiomyopathy (in which thickening of the left ventricular walls limits cardiac output) by inhibiting cardiac sarcomere contractility. The molecule is reaches steady state within two weeks of dosing in a Ph. I trial rather than over six weeks for mavacamten, is safe and well-tolerated in healthy volunteers, and has low risk of DDIs with no significant cytochrome P450 induction or inhibition risk. The indoline starting point was discovered in a high-throughput phenotypic screen…

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: